top of page
NuvOx Announces First Patient Dosed for its EXTEND trials: novEl oXygen ThErapeutic NanO2 for mild respiratory distress in Phase Ib and ARDS in Phase II Trials
Tucson, AZ – June 12, 2025 - NuvOx Therapeutics, Inc. (“NuvOx”) announced that the first patient has been dosed for its EXTEND trials :...
6 days ago
NIH Panel - Commercializing SBIR/STTR Technologies
Featuring Co-Founder and Executive Chairman Dr. Evan Unger As Panelist in Commercializing SBIR/STTR Technologies Discussion at 2025 BIO...
Jun 13
NuvOx Announces Receipt of IND for Study of NanO2 as Cardioprotectant in Acute Myocardial Infarction
NuvOx Announces Receipt of IND for Study of NanO2 as Cardioprotectant in Acute Myocardial Infarction Tucson, AZ – March 4, 2025 - NuvOx...
Mar 17
NuvOx Announces MHRA Approval to Commence Phase IIb Stroke Trial
Tucson, AZ – January 21,2025 - NuvOx Therapeutics, Inc. (“NuvOx”) announced that The Medicines and Healthcare products Regulatory Agency...
Feb 12
NuvOx Announces Two New Publications
NuvOx Announces Two New Publications Tucson, AZ – October 21, 2024 - Co-Founders, Dr. Evan Unger and Dr. Jennifer LH Johnson combine...
Oct 28, 2024
NuvOx’s Co-Founder, Dr. Evan Unger, Receives 2024 Harry Fischer Award for Excellence in Contrast Media Research
Tucson, AZ – October 9, 2024 - Dr. Evan Unger, Executive Chairman of NuvOx Therapeutics (NuvOx), has been awarded the 2024 Harry Fischer...
Oct 14, 2024
NuvOx Pharma LLC Announces Receipt of Qualified Person’s Declaration Equivalence to UK / EU GMP for Investigational Medical Products
Tucson, AZ, September 6th, 2024 – NuvOx Pharma LLC, a wholly owned subsidiary of NuvOx Therapeutics Inc. (together, “NuvOx”) announced...
Sep 17, 2024
NuvOx Pharma LLC Announces Authorization of ARDS Trial from Health Canada
Tucson, AZ, June 30th, 2024 – NuvOx Pharma LLC (“NuvOx”) announced that it has received authorization from Health Canada for its EXTEND:...
Jul 11, 2024
NuvOx Pharma Announces Issuance of a New Patent
Tucson, AZ, January 2, 2024 - NuvOx Pharma has been issued US Patent No. 11,857,627, entitled “Fractionated Radiotherapy and...
Jan 8, 2024
NuvOx Announces Contract to Support NOVEL Trial
Tucson, AZ, USA, October 31, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic...
Nov 2, 2023
NuvOx Therapeutics Wins Most Fundable Company by Pepperdine Graziadio Business School
Tucson, AZ, September 28th, 2023 NuvOx Therapeutics (“NuvOx”) is delighted to announce that it achieved the Gold Level recognition on the...
Oct 2, 2023
NuvOx Closed Oversubscribed Convertible Notes
Tucson, AZ, September 18th, 2023 NuvOx Therapeutics (“NuvOx”) announced that it has closed an oversubscribed convertible notes round,...
Sep 25, 2023
NuvOx Announces Publication of Research Article in Cancer Research Communication
Tucson, AZ, August 28th, 2023 NuvOx Pharma announced publication of a research article, “Dodecafluoropentane Emulsion as a...
Aug 30, 2023
NuvOx Announces BARDA Partnership for a Phase Ib ARDS/COVID Trial in Canada
Tucson, AZ, August 4th, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to...
Aug 14, 2023
NuvOx Announces Glioblastoma Patient Treatment for Phase IIb RESTORE Trial
Tucson, AZ, May 30, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to treat...
Jun 7, 2023
bottom of page